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Abstract
Background: Acute liver failure (ALF) is uncommon but progresses rapidly with high mortality. We investigated the
incidence, etiologies, outcomes, and predictive factors for 30-day mortality in patients with ALF.
Methods: We conducted a population-based study of ALF patients hospitalized between 2009 and 2013 from the
Thai Nationwide Hospital Admission database, which comprises 76% of all admissions from 858 hospitals across 77
provinces in Thailand. ALF was diagnosed using ICD-10 codes K72.0 and K71.11. Patients with liver cirrhosis were
excluded.
Results: There were 20,589 patients diagnosed with ALF during the study period with 12,277 (59.6%) males and
mean age of 46.6 ± 20.7 years. The incidence of ALF was 62.9 per million population per year. The most frequent
causes of ALF were indeterminate (69.4%), non-acetaminophen drug-induced (26.1%), and viral hepatitis (2.5%).
Acetaminophen was the presumptive cause in 1.7% of patients. There were 5502 patients (26.7%) who died within
30 days after admission. One patient (0.005%) underwent liver transplantation. The average hospital stay was 8.7 ±
13.9 days, and the total cost of management was 1075.2 ± 2718.9 USD per admission. The most prevalent
complications were acute renal failure (ARF)(24.2%), septicemia (18.2%), and pneumonia (12.3%). The most
influential predictive factors for 30-day mortality were ARF (HR = 3.64, 95% CI: 3.43–3.87, p < 0.001), malignant
infiltration of the liver (HR = 3.37, 95% CI: 2.94–3.85, p < 0.001), and septicemia (HR = 1.96, 95%CI: 1.84–2.08, p < 0.
001).
Conclusions: ALF patients have poor outcomes with 30-day mortality of 26.7% and high economic burden.
Indeterminate etiology is the most frequent cause. ARF, malignant infiltration of the liver, and septicemia are main
predictors of 30-day mortality.
Keywords: Acute liver failure, Epidemiology, Outcomes, Predictor, Population-based study
Background
Acute liver failure (ALF) is a clinical condition charac-
terized by an acute deterioration of liver function result-
ing in encephalopathy and coagulopathy (International
Normalized Ratio: INR ≥ 1.5), which occurs within 8–26
weeks of the onset of symptoms in patients without pre-
existing liver disease [1–3]. However, the definitions
have variations in time course and etiology [1–4]. Acet-
aminophen and drug toxicity, viral hepatitis, auto-
immune hepatitis, and indeterminate ALF are the most
frequent causes of ALF. There are different predominant
causes of ALF for each geographical area and ethnicity
[5–7]. In the United States and European countries,
acetaminophen toxicity is the predominant cause, while
acute viral hepatitis infection is common in South and
East Asia [5–10].
ALF is an uncommon condition, and the average inci-
dence is approximately 5.5–6.2 people per milllion
population per year [11, 12]. However, patients with ALF
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often rapidly progress to multiorgan failure and have a
high mortality rate. Providing good supportive care in
the intensive care unit, including cardiovascular moni-
toring, intracranial pressure (ICP) monitoring, and venti-
lator support, are important in the management of
patients with ALF. Emergency liver transplantation re-
mains the only definitive treatment for patients who do
not achieve spontaneous recovery. However, a minority
of ALF patients (7–18%) could receive emergency liver
transplantation [13–15]. The in-hospital survival rates of
patients with ALF treated with and without liver trans-
plantation are 80–86% and 35–48%, respectively [9, 15].
Identifying the predictive factors of mortality is import-
ant and may lead to early intensive care treatment and
consideration for emergency liver transplantation. Thus,
this study aimed to determine the predominant causes,
clinical outcomes, and prognostic factors of ALF. We con-
ducted a nationwide population-based cohort study of pa-
tients with ALF during a 5-year period to evaluate the
incidence, etiologies, clinical outcomes, economic burden,
and predictive factors of 30-day mortality.
Methods
Study population and data acquisition
Data were obtained from the discharge records of hospital-
ized patients whose medical treatment expenses were cov-
ered by the Universal Coverage Scheme (UCS). The data
contained 76% of all admissions from primary, secondary,
and tertiary hospitals across 77 provinces in Thailand. The
National Health Security Office (NHSO) reviewed and im-
proved the quality of the 28,294,685 admission summary
records in the database starting from 2009 until 2013,
which aimed to examine the epidemiology and outcomes of
patients hospitalized with gastrointestinal or liver diseases
in Thailand. In the current study, we investigated the
demographic data, co-morbidities, causes of ALF, thera-
peutic procedures, clinical outcomes, and medical expense
of ALF patients enrolled in the NHSO database during
these 5-year period.
The study enrolled patients who were hospitalized for
ALF and diagnosed for the first time using codes K72.0
(Acute and subacute hepatic failure) and K 71.11 (Toxic
liver disease with hepatic necrosis, with coma) of the
International Classification of Diseases, 10th revision
(ICD-10) from January 1, 2009 to December 31, 2013 ac-
cording to the NHSO database. Patients who had preex-
isting liver cirrhosis (K74) were excluded. The diagnosis
of ALF, co-morbidities, and treatment considerations
were performed by attending physicians based on clin-
ical data and laboratory investigations in each hospital.
Patients with ALF were diagnosed based on the compat-
ible criteria as the onset of hepatic encephalopathy oc-
curring within 26 weeks of the onset of jaundice in
patients with no preexisting cirrhosis [3].
Co-morbidities, etiologies, and complications were
identified using following codes: cerebrovascular disease
(I60–69), ischemic heart disease (I20–25), diabetes melli-
tus (E08–13), chronic obstructive pulmonary disease
(J44), chronic kidney disease (N18–19), hepatitis A virus
infection (B15), hepatitis B virus infection (B16, B18.0,
and B18.1), hepatitis C virus infection (B17.1 and B18.2),
hepatitis E virus infection (B17.2), autoimmune hepatitis
(K75.4), vascular liver diseases (I82.0, K76.3 and K76.5),
malignant neoplasms of liver and intrahepatic bile duct
(C22), adverse effect of 4-aminophenol derivatives
(T39.1), acute renal failure (ARF)(N17), septicemia (A
41), pneumonia (J12–18), and urinary tract infection
(N39). Patients were classified as indeterminate ALF
when no etiological factor was identified. Therapeutic
procedures were identified using ICD-9 procedure
codes: liver transplantation (50.5), hemodialysis (39.95),
antibiotic usage (99.21), blood transfusion (99.00–99.09),
plasma exchange (99.71), ICP monitoring (01.10) and
ventilator support (96.7). The additional ICD-10 external
cause index was used to identify the etiologies of
drug-induced ALF (T36-T65).
The study protocol was approved by the Institutional
Review Board (IRB 113/58) of the Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand. The study
was conducted in accordance with the ethical principles
of the Declaration of Helsinki under good clinical prac-
tice. The data were used by the Gastroenterological As-
sociation of Thailand (GAT) with an agreement from
the NHSO.
Definitions
Most government hospitals in Thailand are operated by
the Ministry of Public Health and are classified into
three levels. Primary hospitals are community hospitals
at the district level and have capacities of 10–200 beds.
Secondary hospitals are general hospitals in major dis-
tricts and have capacities of 200–500 beds. Tertiary hos-
pitals are regional hospitals in provincial centers and
have capacities of at least 500 beds and specialist
physicians.
Statistical analysis
Categorical data are presented as numbers (percentages),
and continuous data are shown as the mean ± standard
deviation (SD). Comparison the difference between base-
line characteristics, clinical outcomes and therapeutic
procedures in patients who died and survived within 30
days is carried out using the chi-square test or Fisher’s
exact test for categorical variables and the unpaired
t-test or Mann-Whitney U test for continuous variables.
Two-sided P-values < 0.05 were considered statistically
significant. Cox proportional hazards regression analysis
was used to identify independent predictive factors for
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30-day mortality, and the results are shown as the haz-
ard ratio (HR) and 95% confidence interval. All analyses
were performed using SPSS software version 22.0 (IBM,
New York city, NY, USA).
Results
Patient characteristics
Between January 2009 and December 2013, the inci-
dence due to all-cause admissions was 5.6 million cases
per year. Of these, a total of 159,061 admissions (or
21,165 admissions per year) were due to liver diseases,
and 20,589 admissions (or 4117 admissions per year)
were diagnosed with ALF and enrolled in this study. The
annual admission rate for ALF was 0.07% of the total ad-
missions per year and 19.4% of all admissions related to
liver disease. According to the data from the National
Statistical Office of Thailand (NSO), the estimated rate
for the Thai population was 65.4 million people per year.
The incidence of ALF in Thailand was 62.9 cases per mil-
lion people per year in the present study. The mean age of
hospitalized patients with ALF was 46.6 ± 20.7 years, and
12,277 patients were male (59.6%). Most of the patients
were hospitalized in primary hospitals (n = 13,297, 64.6%)
and in the Northeast part of Thailand (n = 8001, 38.9%).
The patient’s baseline characteristics and co-morbidities
were shown in Table 1.
The etiologies of ALF in Thailand were indeterminate
cause (69.4%), non-acetaminophen drug-induced (26.1%),
viral hepatitis (2.5%), acetaminophen toxicity (1.7%), and
other causes (0.3%). From the available recorded informa-
tion (298 admissions), the main causes of non-acetami
nophen drug-induced ALF were systemic antimycobacter-
ial drugs (T37.1 and T36.6) (39.3%), systemic antibacterial
antibiotics (T36.0–36.5, T36.8–36.9) (9.1%), and antiviral
drugs (T37.5) (6.0%).
Clinical outcomes and complications
The overall in-hospital and 30-day mortality rates of pa-
tients with ALF were 18.4% (n = 3792) and 26.7% (n =
5502), respectively. The mean length of hospital stay was
8.7 ± 13.9 days. The complications among patients with
ALF were ARF (24.2%), septicemia (18.2%), pneumonia
(12.3%), and urinary tract infection (4.2%). At the time of
study enrollment, 19.5% received mechanical ventilation,
and 2.4% of patients required renal replacement therapy.
One patient (0.005%) underwent liver transplantation.
The mean cost per hospital admission for ALF was
1075.2 ± 2718.9 United States dollar (USD). The total
medical expense of admission was 23 million USD per
year. Of this amount, 4.2 million USD per year was
spent but could not sustain the lives of patients. ALF pa-
tients who died within 30 days after admission had
greater age (51.7 ± 20.6 vs. 44.7 ± 20.4 years, p < 0.001), a
greater proportion of males (63.0% vs. 58.4%, p < 0.001),
more co-morbidities (28.9% vs. 16.8%, p < 0.001), and
more cases of indeterminate cause (73.6% vs. 67.9%)
compared to patients who survived within 30 days (Table
1). In terms of clinical outcomes and interventions, the
patients who died within 30 days after admission had
shorter lengths of hospital stays, had significantly more
complications (including ARF, septicemia, pneumonia,
and urinary tract infections), and needed more blood
transfusion, renal replacement therapy, plasma exchange
and mechanical ventilator support (Table 2). No patient
was treated with liver dialysis or monitored ICP in this
database.
Predictors for 30-day mortality
Multivariate Cox regression analysis was performed to
identify the predictor for 30-day mortality by including
potential factors from univariate Cox regression analysis.
Table 3 presents the independent predictive factors for
30-day mortality among hospitalized patients with ALF.
The three most commons factors associated with 30-day
mortality were ARF (HR = 3.64, 95% CI: 3.43–3.87, p <
0.001), malignant infiltration of the liver (HR = 3.37, 95%
CI: 2.94–3.85, p < 0.001), and septicemia (HR = 1.96,
95%CI: 1.84–2.08, p < 0.001). The ARF, malignant infil-
tration of the liver, and septicemia were observed in
53.1, 4.9 and 37.1% of patients who died in 30 days after
admission compared to 13.7, 0.6 and 11.3% of those who
survived.
Discussion
The main finding of the current study was the incidence
rate of ALF was 62.9 per million population per year in
Thai population with a 30-day mortality rate after hos-
pital admission of 26.7%. In addition, indeterminate eti-
ology (69.4%) was the most common cause of ALF.
Patients have higher risk of death within 30 days after
admission if they have age ≥ 60 years, co-morbidities,
malignant infiltration of the liver, Hepatitis B virus infec-
tion, Hepatitis C virus infection, indeterminate cause,
and complications including ARF, septicemia and
pneumonia.
The true incidence of ALF is unclear because there is
scarce data from previous studies, which were mostly
done in liver transplant units or tertiary referral centers.
The estimated annual incidence of ALF is 5.5 cases per
million population per year in the United States accord-
ing to a population-based study and 6.2 cases per million
population per year in Scotland in liver transplant cen-
ters [11, 12]. Our study included data from primary, sec-
ondary, and tertiary hospitals and showed a higher
incidence rate of ALF in comparison to these studies.
However, the incidence rate from our study is close to
that reported by Ho et al., who found an annual inci-
dence rate of 80.2 cases per million person-years in
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Taiwanese hospitalized patients with ALF [7]. These data
might indicate that ALF is not a rare condition in some
countries, including Thailand.
The etiology of ALF is an important factor for progno-
sis and management. The main causes of ALF are differ-
ent in each area of the world. The predominant cause of
ALF is acetaminophen in the United States, the United
Kingdom, and Australia (36–43%) [16–18]. In Asian
countries, the predominant causes are acute hepatitis
virus infection, specifically hepatitis E virus in India
(43.9%) [19] and hepatitis B virus in Japan (32.7%) and
Taiwan (33%) [7, 20]. Indeterminate cause is the leading
etiology of ALF in Scandinavian countries (43%), Chile
(44%), and Sudan (38%) [21–23]. There were no
previous data on etiology in adult patients with ALF in
Thailand. However, data from a single tertiary care hos-
pital reported that indeterminate cause (55%) was the
main etiology among hospitalized Thai children with
ALF [24]. Our study showed that indeterminate cause
(69.4%) is the predominant etiology of ALF in Thailand.
Of the established causes, non-acetaminophen drug tox-
icity (26.1%) was the most frequent. Thailand has a high
burden of chronic hepatitis B infection with an esti-
mated prevalence of 3.5% of the population [25]. How-
ever, our study showed that acute hepatitis B-induced
ALF occurred in only 1.8% of patients, which might be
underestimated because the diagnosis may be difficult by
routine serology.
Table 1 Baseline characteristics and demographic of patients hospitalized with acute liver failure during 2009 to 2013
Variables Survived≥ 30 days (n = 15,087) Died within 30 days (n = 5502) p-value
Age, years 44.8 ± 20.4 51.7 ± 20.6 < 0.001
Male, n (%) 8810 (58.4%) 3467 (63.0%) < 0.001
Hospital level
Primary, n (%) 9813(65.0%) 3484 (63.3%) 0.02
Secondary, n (%) 2789 (18.5%) 975 (17.7%) 0.21
Tertiary, n (%) 1106 (7.3%) 374 (6.8%) 0.19
Others, n (%) 1379 (9.1%) 669 (12.2%) < 0.001
Residence by region < 0.001
Central, n (%) 3187 (21.1%) 1254 (22.8%) 0.01
Northeast, n (%) 6075 (40.3%) 1926 (35.0%) < 0.001
North, n (%) 1676 (11.1%) 775 (14.1%) < 0.001
South, n (%) 1281 (8.5%) 523 (9.5%) 0.02
Others, n (%) 2865 (19.0%) 1024 (18.6%) 0.54
Co-morbidity
Cerebrovascular disease, n (%) 111 (0.7%) 99 (1.8%) < 0.001
Ischemic heart disease, n (%) 435 (2.9%) 376 (6.8%) < 0.001
Diabetes mellitus, n (%) 1302 (8.6%) 584 (10.6%) < 0.001
Chronic obstructive pulmonary disease, n (%) 304 (2.0%) 242 (4.4%) < 0.001
Chronic kidney disease, n (%) 392 (2.6%) 291 (5.3%) < 0.001
Etiology
Hepatitis A virus, n (%) 16 (0.1%) 4 (0.1%) 0.50
Hepatitis B virus, n (%) 228 (1.5%) 139 (2.5%) < 0.001
Hepatitis C virus, n (%) 84 (0.6%) 53 (1.0%) 0.001
Hepatitis E virus, n (%) 1 (0.00007%) 0 0.55
Acetaminophen, n (%) 323 (2.1%) 26 (0.5%) < 0.001
Non-acetaminophen drugs, n (%) 4363 (28.9%) 1011 (18.4%) < 0.001
Autoimmune, n (%) 7 (0.0005%) 8 (0.1%) 0.02
Vascular cause, n (%) 17 (0.1%) 21 (0.4%) < 0.001
Malignant infiltration, n (%) 88 (0.6%) 272 (4.9%) < 0.001
Other, n (%) 7 (0.0005%) 3 (0.1%) 0.82
Indeterminate, n (%) 10,250 (67.9%) 4049 (73.6%) < 0.001
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Table 2 Clinical outcomes, requirement of therapeutic procedures and medical expense in hospitalized patients with ALF during
2009–2013
Survived≥ 30 days (n = 15,087) Died within 30 days (n = 5502) p-value
Length of stay (days) 9.7 ± 15.6 6.1 ± 6.5 < 0.001
Complication
Acute renal failure, n (%) 2062 (13.7%) 2923 (53.1%) < 0.001
Septicemia, n (%) 1703 (11.3%) 2041 (37.1%) < 0.001
Pneumonia, n (%) 1370 (9.1%) 1156 (21.0%) < 0.001
Urinary tract infection, n (%) 585 (3.9%) 290 (5.3%) < 0.001
Procedure during admission
Liver transplantation, n (%) 1 (0.00007%) 0 0.55
Renal dialysis, n (%) 188 (1.2%) 309 (5.6%) < 0.001
Ventilator, n (%) 1125 (7.5%) 2895 (52.6%) < 0.001
Antibiotic usage, n (%) 381(2.53%) 156(2.84%) 0.22
Blood transfusion, n (%) 2470(16.4%) 2068(37.6%) < 0.001
Plasma exchange, n (%) 3(0.02%) 8 (0.14%) 0.001
Costs per admission (USD) 959.4 ± 2884.1 1392.8 ± 2172.3 < 0.001
USD United States dollars
Table 3 Predictive factor for 30-day mortality in patients with ALF
Adjusted Hazard Ratio 95% CI p-value
Primary hospital 1.08 1.02–1.14 0.01
Residence in central region 1.02 0.95–1.08 0.66
Age≥ 60 years 1.29 1.22–1.37 < 0.001
Male 0.99 0.94–1.05 0.78
Co-morbidities
Cerebrovascular disease 1.19 0.98–1.46 0.09
Ischemic heart disease 1.32 1.18–1.47 < 0.001
Diabetes mellitus 0.90 0.82–0.98 0.02
Chronic obstructive pulmonary disease 1.20 1.04–1.37 0.01
Chronic kidney disease 1.32 1.17–1.48 < 0.001
Etiologies
Hepatitis A virus 0.85 0.32–2.27 0.75
Hepatitis B virus 1.44 1.21–1.72 < 0.001
Hepatitis C virus 1.37 1.04–1.81 0.03
Acetaminophen 0.47 0.32–0.69 < 0.001
Autoimmune hepatitis 1.35 0.67–2.70 0.40
Vascular cause 1.27 0.82–1.95 0.29
Malignant infiltration 3.37 2.94–3.85 < 0.001
Indeterminate 1.15 1.07–1.24 < 0.001
Complications
Renal failure 3.64 3.43–3.87 < 0.001
Septicemia 1.96 1.84–2.08 < 0.001
Pneumonia 1.24 1.16–1.33 < 0.001
Urinary tract infection 0.75 0.66–0.84 < 0.001
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In terms of outcome after hospital admission, many
ALF patients have complications such as infections and
multiple organ failures, high mortality, and require high
cost for management. Among the complications, ARF is
the most frequent non-hepatic organ failure in patients
with ALF (24.2%) in the current study. The overall
in-hospital and 30-day mortality rates of hospitalized
ALF patients were 18.4 and 26.7%, respectively. Previous
single center study from the United Kingdom by R Mar-
udanayagam et al. reported that the 30-day mortality
was 26.7% without liver transplant and 13.7% with liver
transplant in ALF patients who were admitted between
January 1992 and May 2008. Additionally, a study by G
Ostapowicz et al. enrolled ALF patients from 17 tertiary
care liver centers around the United States between
January 1998 and May 2001 and showed that the 30-day
mortality rates of 57% without liver transplant and 16%
with liver transplant [17, 26]. Acetaminophen overdose
was the most common cause of ALF in both studies.
Liver transplantation was done in 21.3 and 29% of ALF
patients in the R Marudanayagam et al. study and the G
Ostapowicz et al. study, respectively. Liver transplant-
ation is considered a proven therapy for improving sur-
vival in patients with ALF. In our cohort, only one
patient underwent liver transplantation due to the rapid
progression of the disease and the limitations of the
transplant system. From 2009 to 2013, Thailand had
nine liver transplant centers, of which eight were located
in the capital city and one was located in the northeast-
ern region. According to the Thai Red Cross Organ Do-
nation Center Database, there are approximately 87–158
donors and only 43–73 patients who received liver
transplantation annually. Our information could be use-
ful for improving health care policy for the management
of ALF and promoting public awareness of organ
donation.
Identifying patients who have poor survival outcomes
is essential and will lead to prompt referral and consid-
eration for emergency liver transplantation. Previous
studies show that encephalopathy, extrahepatic organ
failure (especially renal failure), and coagulopathy are
poor prognostic factors for mortality [27]. In addition,
short-term outcome varies according to etiology. The fa-
vorable prognosis was found with acetaminophen- and
ischemic-induced ALF (60–80% short-term survival
without transplantation) and poor prognosis with hepa-
titis B infection, indeterminate cause and drug other
than acetaminophen-related ALF (17–25% short-term
survival without transplantation) [17, 26]. Consistent
with our study, acetaminophen is inversely associated
with the 30-day mortality in patients with ALF. Patients
with acetaminophen-induced ALF had favorable progno-
sis possibly due to the availability of anti-dote (N-acetyl-
cysteine: NAC) and prompt therapy from history of drug
usage. Previous study showed 66 % of patients had spon-
taneous recovery with NAC and supportive care therapy
[17, 28]. Additionally, age ≥ 60 years, co-morbidities, ma-
lignant infiltration, Hepatitis B or C virus infection, inde-
terminate etiology, infectious complications including
ARF, septicemia and pneumonia are independent predic-
tors for 30-day mortality as well.
This study has some limitations. First, it was a retro-
spective study; there may have been some missing data
and uncontrolled exposure. Furthermore, it relies on ac-
curate data recordkeeping. Second, it might be interesting
if we could analyze the difference of the model for
end-stage liver disease (MELD) scores in patients with
acute liver failure who died and survived within 30 days.
However, some information about clinical findings and la-
boratory tests were lacking in the NHSO database, pre-
cluding us for estimating this score. Third, our study may
not represent the true prevalence of indeterminate-ALF in
Thailand; we hypothesized that several reasons led to a
large number of indeterminate causes in our study, in-
cluding (i) unavailability of further laboratory investiga-
tions in all hospitals especially in primary hospitals where
the majority of ALF patients were hospitalized, (ii)
co-existence of several potential etiologies possibly con-
founding the final diagnosis by attending physician, (iii)
missing data and the inability to get a precise history due
to encephalopathy. A recent publication shows that using
diagnostic algorithms and expert review in combination
with additional laboratory testing can verify etiologic diag-
noses in 50% of patients initially considered as indetermi-
nate-ALF [29].
Conclusions
The incidence rate of ALF in Thailand is 62.9 cases per
million population per year. Indeterminate causes are
the major cause, and non-acetaminophen drug-induced
is the most common identifiable cause of ALF cases. Pa-
tients with ALF have high 30-day mortality and high
economic burden. Age, etiologies and complications of
ALF are predictive factors of 30-day mortality after hos-
pital admission.
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